Osimertinib 99% white powder GB0301 Greenbo
2 Inquiries
1421373-65-0
Pharmaceutical Grade
99%
Shanghai
Greenbo
25kg Drum
Yes
2022-07-31
Active Pharm Ingredients,Chemical Catalyst,Pharmaceutical Intermediates,Flavors and Fragrances,Agrochemicals,Chemical Pesticides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceChEBI: A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treat ent of EGFR T790M mutation positive non-small cell lung cancer.AZD-9291 (Mesylate), also known as Osimertinib, belongs to a third-generation EGFR (epidermal growth factor receptor) inhibitor. It can be used for the treatment of locall
Osimertinib is a member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer. It has a role as an antineoplastic agent and an epidermal growth factor receptor antagonist. It is a member of indoles, an aminopyrimidine, a biaryl, a secondary amino compound, a tertiary amino compound, a monomethoxybenzene, a member of acrylamides, a substituted aniline and a secondary carboxamide. It is a conjugate base of an osimertinib(1+).|Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.|Osimertinib is a Kinase Inhibitor. The mechanism of action of osimertinib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor.|Osimertinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC). Osimertinib is associated with a moderate rate of serum aminotransferase elevations during therapy and rare instances of clinically apparent acute liver injury.|Osimertinib is a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.Basic Info-
Product Name:
Osimertinib
Other Name:2-Propenamide,N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-;N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide;AZD 9291;Osimertinib;Tagrisso;1610419-47-0
CAS No.:1421373-65-0
Molecular Formula:C28H33N7O2
InChIKeys:InChIKey=DUYJMQONPNNFPI-UHFFFAOYSA-N
Molecular Weight:499.61
Exact Mass:499.61
UNII:3C06JJ0Z2O
NCI Thesaurus Code:C116377
ATC Code:L01XE|L - Antineoplastic and immunomodulating agents
HScode:29339900
Categories:
Characteristics-
PSA:
87.6
XLogP3:3.7
Density:1.19±0.1 g/cm3(Predicted)
Refractive Index:1.618
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Active Pharm Ingredients,Chemical Catalyst,Pharmaceutical Intermediates,Flavors and Fragrances,Agrochemicals,Chemical Pesticides
-
Location:
Zone K,Zwei Tianyuan Dushi Est,New Industial Park,High-tech Zone, Xian City,Shaanxi
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15 days
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2017
Company Certificates-
international trade license
-
FSSC2000
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
Puerto Rico
Osimertinib
1 KG May 29, 2025 
Bangladesh
Osimertinib
1 MT Sep 9, 2024 Post an enquiry for this product
More from this Seller
-
-
![Cyclobutyl bromide 99% high purity certified Professional Producer Greenbo]( "Cyclobutyl bromide 99% high purity certified Professional Producer Greenbo")
-
Cyclobutyl bromide 99% high purity certified Professional Producer Greenbo
Pharmaceutical Grade / 99%
-
-
-
![Sodium gualenate 99% high purity certified Professional producer Greenbo]( "Sodium gualenate 99% high purity certified Professional producer Greenbo")
-
Sodium gualenate 99% high purity certified Professional producer Greenbo
Industrial Grade / 99%
-
-
-
![L(+)-Lactic acid 99% high purity certified Professional producer Greenbo]( "L(+)-Lactic acid 99% high purity certified Professional producer Greenbo")
-
L(+)-Lactic acid 99% high purity certified Professional producer Greenbo
Industrial Grade / 99%
-
-
-
![4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE 99% high quality Professional Producer Greenbo]( "4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE 99% high quality Professional Producer Greenbo")
-
4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE 99% high quality Professional Producer Greenbo
Pharmaceutical Grade / 99%
-
![4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE 99% high quality Professional Producer Greenbo](https://file.echemi.com/fileManage/upload/goodpicture/20220621/m20220621155320825.jpg "4-CHLORO-1H-PYRROLO[2,3-B]PYRIDINE-5-CARBALDEHYDE 99% high quality Professional Producer Greenbo")